
Search
Filter Results
Displaying 21–30 of 1087 results
-
- May 18, 2025
- 10:00 a.m. (EST)
- 355 Water Street SE, Washington, DC 20003
Since its inception in the Spring of 2006, VisionWalk has raised over $71 million to fund sight-saving research. Join your VisionWalk community! Together, we step closer to fighting blinding diseases.
-
Quarterly Vision Webinar – Mental Health | May 17, 2025
- May 17, 2025
- 12:00 p.m. (EDT)
- Virtual
Join us on Saturday, May 17, at noon Eastern time for a comprehensive webinar covering the emotional challenges vision loss can bring to our community.
-
Arizona Chapter May Networking Meeting
- May 17, 2025
- 10:00 a.m. (MDT)
- 817 E Harmont Dr, , Phoenix, AZ 85020
Board games and brunch potluck.
-
- May 17, 2025
- 10:00 a.m.
- 400 Estabrook Pkwy, Shorewood, WI
Since its inception in the Spring of 2006, VisionWalk has raised over $71 million to fund sight-saving research. Join your VisionWalk community! Together, we step closer to fighting blinding diseases.
-
- May 17, 2025
- 9:00 a.m. (PDT)
- 16801 Euclid Street, Fountain Valley, CA 92708
Since its inception in the Spring of 2006, VisionWalk has raised over $71 million to fund sight-saving research. Join your VisionWalk community! Together, we step closer to fighting blinding diseases.
-
Colorado Vision Connection Spring, 2025
- May 17, 2025
- 8:00 a.m. - 11:30 a.m. (MDT)
- 1675 Aurora Ct, Aurora, CO 80045
Updates on inherited retinal diseases, age-related macular degeneration, and the whole eye transplant program.
-
Well-prepared estate plan brings peace of mind—knowing your loved ones are cared for and your wishes will be honored. It also offers a unique opportunity to leave a lasting impact on a cause important to you.
-
D.C. Metro Chapter Volunteer Opportunities
The DC Chapter is growing! Join our young professionals events for the Foundation Fighting Blindness, or become a part of the Young Professionals Committee.
-
May 15, 2025
ARVO 2025 News: J&J’s XLRP Gene Therapy Didn’t Meet Primary Endpoint in Phase 3 Clinical Trial
Despite missing the primary endpoint, the treatment improved vision for some patients.
-
May 13, 2025
The company is planning a Phase 2/3 clinical trial for the therapy in late 2025.